For example, in non-small-cell lung cancer (NSCLC), mutations in the structural domain of the epidermal growth factor receptor (EGFR) kinase render patients resistant to EGFR inhibitors such as gefitinib and erlotinib [57,58]. Here, EGFR is linked to non-small cell lung carcinoma.